We used specific antisera and immunohistochemical methods to investigate the subcellular localization and expression of Bcr, Abl, and Bcr-Abl proteins in leukemic cell lines and in fresh human leukemic and normal samples at various stages of myeloid differentiation. Earlier studies of the subcellular localization of transfected murine type IV c-Abl protein in fibroblasts have shown that this molecule resides largely in the nucleus, whereas transforming deletion variants are localized exclusively in the cytoplasm. Here, we demonstrate that the murine type IV c-Abl protein is also found in the nucleus when overexpressed in a mouse hematopoietic cell line. However, in both normal and leukemic human hematopoietic cells, c-Abl is discerned predominantly in the cytoplasm, with nuclear staining present, albeit at a lower level. In contrast, normal endogenous Bcr protein, as well as the aberrant p210BCR-ABL and p190BCR-ABL proteins consistently localize to the cytoplasm in both cell lines and fresh cells. The results with p210BCR-ABL were confirmed in a unique Ph1-positive chronic myelogenous leukemia (CML) cell line, KBM5, which lacks the normal chromosome 9 and hence the normal c-Abl product. Because the p210BCR-ABL protein appears cytoplasmic in both chronic phase and blast crisis CML cells, as does the p190BCR-ABL in Ph1-positive acute leukemia, a change in subcellular location of Bcr-Abl proteins between cytoplasm and nucleus cannot explain the different spectrum of leukemias associated with p210 and p190, nor the transition from the chronic to the acute leukemia phenotype seen in CML. Further analysis of fresh CML and normal hematopoietic bone marrow cells reveals that p210BCR-ABL, as well as the normal Bcr and Abl proteins, are expressed primarily in the early stages of myeloid maturation, and that levels of expression are reduced significantly as the cells mature to polymorphonuclear leukocytes. Similarly, a decrease in Bcr and Abl levels occurs in HL-60 cells induced by DMSO to undergo granulocytic differentiation. The action of p210BCR-ABL and its normal counterparts may, therefore, take place during the earlier stages of myeloid development.
M Wetzler, M Talpaz, R A Van Etten, C Hirsh-Ginsberg, M Beran, R Kurzrock
Title and authors | Publication | Year |
---|---|---|
The FABD domain is critical for the oncogenicity of BCR/ABL in chronic myeloid leukaemia
Zheng R, Wei W, Liu S, Zeng D, Yang Z, Tang J, Tan J, Huang Z, Gao M |
Cell communication and signaling : CCS | 2024 |
Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance
Eshaq AM, Flanagan TW, Hassan SY, Al Asheikh SA, Al-Amoudi WA, Santourlidis S, Hassan SL, Alamodi MO, Bendhack ML, Alamodi MO, Haikel Y, Megahed M, Hassan M |
Cancers | 2024 |
SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia.
Brown LM, Hediyeh-Zadeh S, Sadras T, Huckstep H, Sandow JJ, Bartolo RC, Kosasih HJ, Davidson NM, Schmidt B, Bjelosevic S, Johnstone R, Webb AI, Khaw SL, Oshlack A, Davis MJ, Ekert PG |
Blood Advances | 2022 |
Advances in Precision Medicine Oncology
H Arnouk, BA Hassan |
2021 | |
Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes
J Stetka, J Gursky, JL Velasquez, R Mojzikova, P Vyhlidalova, L Vrablova, J Bartek, V Divoky |
Cancers | 2020 |
Identification of Phosphate-Containing Compounds as New Inhibitors of 14-3-3/c-Abl Protein–Protein Interaction
L Iralde-Lorente, G Tassone, L Clementi, L Franci, CC Munier, Y Cau, M Mori, M Chiariello, A Angelucci, MW Perry, C Pozzi, S Mangani, M Botta |
ACS chemical biology | 2020 |
Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update
L Bavaro, M Martelli, M Cavo, S Soverini |
International journal of molecular sciences | 2019 |
The interaction between PLEKHG2 and ABL1 suppresses cell growth via the NF-κB signaling pathway in HEK293 cells
M Nishikawa, S Nakano, H Nakao, K Sato, T Sugiyama, Y Akao, H Nagaoka, H Yamakawa, T Nagase, H Ueda |
Cellular Signalling | 2019 |
Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway
K Kurmi, S Hitosugi, J Yu, F Boakye-Agyeman, EK Wiese, TR Larson, Q Dai, YJ Machida, Z Lou, L Wang, JC Boughey, SH Kaufmann, MP Goetz, LM Karnitz, T Hitosugi |
Cell Metabolism | 2018 |
Paradoxical counteraction by imatinib against cell death in myeloid progenitor 32D cells expressing p210BCR-ABL
M Takita, F Tsukahara, T Mishima, K Ieguchi, M Yamada, H Honda, Y Maru |
Oncotarget | 2018 |
The Molecular Basis of Human Cancer
WA Ricke, K Williams, J Wynder, G Palapattu, Y Wang, GR Cunha |
The Molecular Basis of Human Cancer | 2017 |
Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells
Q Li, Z Huang, M Gao, W Cao, Q Xiao, H Luo, W Feng |
International journal of molecular sciences | 2017 |
Pleckstrin homology domain of p210 BCR-ABL interacts with cardiolipin to regulate its mitochondrial translocation and subsequent mitophagy
K Shimasaki, M Watanabe-Takahashi, M Umeda, S Funamoto, Y Saito, N Noguchi, K Kumagai, K Hanada, F Tsukahara, Y Maru, N Shibata, M Naito, K Nishikawa |
Genes to Cells | 2017 |
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases
Y Dasgupta, M Koptyra, G Hoser, K Kantekure, D Roy, B Gornicka, M Nieborowska-Skorska, E Bolton-Gillespie, S Cerny-Reiterer, M Muschen, P Valent, MA Wasik, C Richardson, O Hantschel, H der Kuip, T Stoklosa, T Skorski |
Blood | 2016 |
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned
B Linder, J Pinilla-Ibarz, K Sweet, G Corrales-Yepez, R Komrokji |
OncoTargets and therapy | 2016 |
Colocalization of cortactin and PH domain of BCR in HEK293T cells and its potential role in cell signaling
DS Gurianov, SV Antonenko, GD Telegeev |
Biopolymers and Cell | 2016 |
Mapk15 mediates bcr-abl1-induced autophagy and regulates oncogene-dependent cell proliferation and tumor formation
D Colecchia, M Rossi, F Sasdelli, S Sanzone, A Strambi, M Chiariello |
Autophagy | 2015 |
Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer
GA de Oliveira, LP Rangel, DC Costa, JL Silva |
Frontiers in Oncology | 2015 |
Targeting Filarial Abl-like Kinases: Orally Available, Food and Drug Administration–Approved Tyrosine Kinase Inhibitors Are Microfilaricidal and Macrofilaricidal
EM O'Connell, S Bennuru, C Steel, MA Dolan, TB Nutman |
The Journal of Infectious Diseases | 2015 |
Chromosomal Translocations and Genome Rearrangements in Cancer
JD Rowley, MM Beau, TH Rabbitts |
2015 | |
Kinase-Independent Mechanisms of Resistance of Leukemia Stem Cells to Tyrosine Kinase Inhibitors
CV Ichim |
Stem Cells Translational Medicine | 2014 |
Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer
JM Drake, JK Lee, ON Witte |
Molecular and cellular biology | 2014 |
Myeloproliferative Disorders
B Meier, JH Burton |
Emergency Medicine Clinics of North America | 2014 |
Strategic therapeutic approaches to overcome emerging dual SRC/ABL kinase inhibitors resistances in chronic phase Ph positive chronic myeloid leukemia
R Rana, S Das, A Swami, D Pon, S Ramesh, SD Kumar |
Asian Journal of Medical Sciences | 2014 |
Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia
SB Foley, ZL Hildenbrand, AA Soyombo, JA Magee, Y Wu, KI Oravecz-Wilson, TS Ross |
Cell Reports | 2013 |
BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives
J Cui, R Fu, LH Zhou, SP Chen, GW Li, SX Qian, S Liu |
Bioorganic & Medicinal Chemistry Letters | 2013 |
Acute myeloblastic leukemia with associated BCR-ABL translocation in a dog
JF Figueiredo, S Culver, E Behling-Kelly, M Breen, KR Friedrichs |
Veterinary Clinical Pathology | 2012 |
BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia
S Roy, HG Jørgensen, P Roy, MA el Baky, JV Melo, G Strathdee, TL Holyoake, C Bartholomew |
British Journal of Haematology | 2012 |
Effective killing of leukemia cells by the natural product OSW-1 through disruption of cellular calcium homeostasis
C Garcia-Prieto, KB Ahmed, Z Chen, Y Zhou, N Hammoudi, Y Kang, C Lou, Y Mei, Z Jin, P Huang |
The Journal of biological chemistry | 2012 |
Effector caspases and leukemia
Y Lu, GQ Chen |
International Journal of Cell Biology | 2011 |
Leukemias: Principles and Practice of Therapy
O Sala-Torra, JP Radich |
Leukemias: Principles and Practice of Therapy | 2011 |
c-Abl in Neurodegenerative Disease
SD Schlatterer, CM Acker, P Davies |
Journal of Molecular Neuroscience | 2011 |
Innovative technology for cancer risk analysis
S Tommas, K Danza, B Pilato, SD Summa |
Annals of Oncology | 2011 |
Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms
MM Barcelos, MC Santos-Silva |
Revista Brasileira de Hematologia e Hemoterapia | 2011 |
BRIT1/MCPH1 Expression in Chronic Myeloid Leukemia and Its Regulation of the G2/M Checkpoint
C Giallongo, D Tibullo, PL Cava, A Branca, N Parrinello, P Spina, F Stagno, C Conticello, A Chiarenza, P Vigneri, GA Palumbo, FD Raimondo |
Acta Haematologica | 2011 |
Changing the Subcellular Location of the Oncoprotein Bcr-Abl Using Rationally Designed Capture Motifs
AS Dixon, JE Constance, T Tanaka, TH Rabbitts, CS Lim |
Pharmaceutical Research | 2011 |
Advances in Cancer Research
M Lemaire, S Deleu, ED Bruyne, EV Valckenborgh, E Menu, K Vanderkerken |
Advances in Cancer Research Volume 110 | 2011 |
Interplay between Kinase Domain Autophosphorylation and F-Actin Binding Domain in Regulating Imatinib Sensitivity and Nuclear Import of BCR-ABL
M Preyer, P Vigneri, JY Wang, GS Wu |
PloS one | 2011 |
Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?
P Valent |
European Journal of Clinical Investigation | 2010 |
The c-Abl tyrosine kinase stabilizes Pitx1 in the apoptotic response to DNA damage
T Yamaguchi, Y Miki, K Yoshida |
Apoptosis | 2010 |
Management of Chronic Myeloid Leukemia with BCR/ABL Inhibitors: Current Status and Future Perspectives
P Valent |
Clinical medicine insights. Therapeutics | 2010 |
Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring
M Zaliova, E Fronkova, K Krejcikova, K Muzikova, E Mejstrikova, J Stary, J Trka, J Zuna |
Leukemia | 2009 |
Proliferating cell nuclear antigen destabilizes c-Abl tyrosine kinase and regulates cell apoptosis in response to DNA damage
X He, C Wei, T Song, J Yuan, Y Zhang, Q Ma, W Shi, H Zhong |
Apoptosis | 2009 |
c-Abl Kinase Is Required for β 2 Integrin-Mediated Neutrophil Adhesion
L Cui, C Chen, T Xu, J Zhang, X Shang, J Luo, L Chen, X Ba, X Zeng |
Journal of immunology (Baltimore, Md. : 1950) | 2009 |
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders
C Walz, NC Cross, RA van Etten, A Reiter |
Leukemia | 2008 |
Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform
P Valent, T Lion, D Wolf, C Sillaber, H Agis, A Petzer, A Lang, P Kalhs, D Geissler, R Greil, W Linkesch, S Burgstaller, J Thaler, G Gastl |
Wiener klinische Wochenschrift | 2008 |
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism
H Zhang, D Trachootham, W Lu, J Carew, FJ Giles, MJ Keating, RB Arlinghaus, P Huang |
Leukemia | 2008 |
An enhanced association of RACK1 with Abl in cells transfected with oncogenic ras
CC Huang, CH Liu, NN Chuang |
The International Journal of Biochemistry & Cell Biology | 2008 |
Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease
P Valent |
British Journal of Haematology | 2008 |
TTK/Mps1 controls nuclear targeting of c-Abl by 14-3-3-coupled phosphorylation in response to oxidative stress
K Nihira, N Taira, Y Miki, K Yoshida |
Oncogene | 2008 |
Nuclear trafficking of pro-apoptotic kinases in response to DNA damage
K Yoshida |
Trends in Molecular Medicine | 2008 |
T cell survival and function requires the c-Abl tyrosine kinase
I Silberman, RV Sionov, V Zuckerman, S Haupt, Z Goldberg, A Strasser, ZS Ben-Sasson, M Baniyash, AJ Koleske, Y Haupt |
Cell cycle (Georgetown, Tex.) | 2008 |
Treatment of Intracerebral Glioblastomas with G422 Tumour Cell Vaccine in a Mouse Model
YH Ma, JB Yu, HP Yao, RY Zhan, JS Zheng |
J INT MED RES | 2008 |
Subcellular distribution of p210BCR-ABL in CML cell lines and primary CD34+ CML cells
H Patel, SB Marley, L Greener, MY Gordon |
Leukemia | 2007 |
Chronic myeloid leukaemia as a model of disease evolution in human cancer
JV Melo, DJ Barnes |
Nature Reviews Cancer | 2007 |
Enterovirus 71 triggering of neuronal apoptosis through activation of Abl-Cdk5 signalling
TC Chen, YK Lai, CK Yu, JL Juang |
Cellular Microbiology | 2007 |
ERK1/2 inactivation and p38 MAPK-dependent caspase activation during guanosine 5′-triphosphate-mediated terminal erythroid differentiation of K562 cells
MA Moosavi, R Yazdanparast, A Lotfi |
The International Journal of Biochemistry & Cell Biology | 2007 |
Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches
P Valent |
Biologics : targets & therapy | 2007 |
Gag Influences Transformation by Abelson Murine Leukemia Virus and Suppresses Nuclear Localization of the v-Abl Protein
CR Yi, N Rosenberg |
Journal of virology | 2007 |
MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage
D Raina, R Ahmad, S Kumar, J Ren, K Yoshida, S Kharbanda, D Kufe |
The EMBO Journal | 2006 |
Role of the C-terminal actin binding domain in BCR/ABL-mediated survival and drug resistance
N Underhill-Day, A Pierce, SE Thompson, D Xenaki, AD Whetton, PJ Owen-Lynch |
British Journal of Haematology | 2006 |
Abl
A Pendergast, P Zipfel |
AfCS-Nature Molecule Pages | 2006 |
Differential effect of leukaemogenic tyrosine kinases on cell motility is governed by subcellular localisation
A Pierce, Y Lu, HG Hamzah, S Thompson, PJ Owen-Lynch, AD Whetton, E Spooncer |
British Journal of Haematology | 2006 |
Detection in primary chronic myeloid leukaemia cells of p210BCR-ABL1 in complexes with adaptor proteins CBL, CRKL, and GRB2
H Patel, SB Marley, MY Gordon |
Genes, Chromosomes and Cancer | 2006 |
Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia
D Primo, J Flores, S Quijano, ML Sanchez, ME Sarasquete, J Pino-Montes, PI Gaarder, M Gonzalez, A Orfao |
British Journal of Haematology | 2006 |
Aberrant FHIT protein expression in classical Hodgkin’s lymphoma: a potential marker
P Zhao, AK Lam, YL Lu, M Zhong, LH Chen, XL Pu |
Pathology | 2006 |
Structural Basis for the Cytoskeletal Association of Bcr-Abl/c-Abl
O Hantschel, S Wiesner, T Güttler, CD Mackereth, LL Rix, Z Mikes, J Dehne, D Görlich, M Sattler, G Superti-Furga |
Molecular Cell | 2005 |
Stress and death: breaking up the c-Abl/14-3-3 complex in apoptosis
AM Pendergast |
Nature Cell Biology | 2005 |
JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage
K Yoshida, T Yamaguchi, T Natsume, D Kufe, Y Miki |
Nature Cell Biology | 2005 |
Philadelphia positive acute lymphoblastic leukaemia of childhood
LK Jones, V Saha |
British Journal of Haematology | 2005 |
TYROSINE KINASE INHIBITORS AND THE DAWN OF MOLECULAR CANCER THERAPEUTICS*
R Tibes, J Trent, R Kurzrock |
Annual Review of Pharmacology and Toxicology | 2005 |
Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors
DR Veach, M Namavari, T Beresten, J Balatoni, M Minchenko, H Djaballah, RD Finn, B Clarkson, JG Gelovani, WG Bornmann, SM Larson |
Nuclear Medicine and Biology | 2005 |
Rho GTPases in Hematopoietic Cells
PB van Hennik, PL Hordijk |
Antioxidants & Redox Signaling | 2005 |
Oncogenes as Novel Targets for Cancer Therapy (Part I): Growth Factors and Protein Tyrosine Kinases
Z Zhang, M Li, ER Rayburn, DL Hill, R Zhang, H Wang |
American Journal of PharmacoGenomics | 2005 |
BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint
J Dierov, R Dierova, M Carroll |
Cancer Cell | 2004 |
Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein
B Scappini, S Gatto, F Onida, C Ricci, V Divoky, WG Wierda, M Andreeff, L Dong, K Hayes, S Verstovsek, HM Kantarjian, M Beran |
Cancer | 2004 |
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation
N Orsolic, FJ Giles, H Gourdeau, M Golemovic, M Beran, J Cortes, EJ Freireich, H Kantarjian, S Verstovsek |
British Journal of Haematology | 2004 |
p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells
S Salesse, SJ Dylla, CM Verfaillie |
Leukemia | 2004 |
BCR/ABL activates mdm2 mRNA translation via the La antigen
R Trotta, T Vignudelli, O Candini, RV Intine, L Pecorari, C Guerzoni, G Santilli, MW Byrom, S Goldoni, LP Ford, MA Caligiuri, RJ Maraia, D Perrotti, B Calabretta |
Cancer Cell | 2003 |
Tyrosine Kinase Inhibitors as Cancer Therapy: Clinical Science Review
GL Nichols |
Cancer Investigation | 2003 |
The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains
M Stanglmaier, M Warmuth, I Kleinlein, S Reis, M Hallek |
Leukemia | 2003 |
Identification of new MHC-restriction elements for presentation of the p210BCR-ABL fusion region to human cytotoxic T lymphocytes
JY Sun, D Senitzer, SJ Forman, S Chatterjee, KK Wong |
Cancer Immunology, Immunotherapy | 2003 |
Bcr-Abl is a “Molecular Switch” for the Decision for Growth and Differentiation in Hematopoietic Stem Cells
T Era |
International Journal of Hematology | 2002 |
p53 expression in K562 cells is associated with caspase-mediated cleavage of c-ABL and BCR-ABL protein kinases
AM di Bacco, TG Cotter |
British Journal of Haematology | 2002 |
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop
S Roumiantsev, NP Shah, ME Gorre, J Nicoll, BB Brasher, CL Sawyers, RA van Etten |
Proceedings of the National Academy of Sciences | 2002 |
Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571
A Klejman, L Rushen, A Morrione, A Slupianek, T Skorski |
Oncogene | 2002 |
Chronic myelogenous leukemia: mechanisms underlying disease progression
AS Shet, BN Jahagirdar, CM Verfaillie |
Leukemia | 2002 |
In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells
B Scappini, F Onida, HM Kantarjian, L Dong, S Verstovsek, MJ Keating, M Beran |
Cancer | 2002 |
Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry
B Falini, DY Mason |
Blood | 2002 |
Mechanisms of Transformation by the BCR/ABL Oncogene
M Sattler, JD Griffin |
International Journal of Hematology | 2001 |
Molecular Biology of Chronic Myeloid Leukemia
Y Maru |
International Journal of Hematology | 2001 |
Philadelphia Chromosome–Positive Acute Lymphocytic Leukemia
JP Radich |
Hematology/Oncology Clinics of North America | 2001 |
Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3
TL Holyoake, X Jiang, HG Jorgensen, S Graham, MJ Alcorn, C Laird, AC Eaves, CJ Eaves |
Blood | 2001 |
Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation
B Bruecher-Encke, JD Griffin, BG Neel, U Lorenz |
Leukemia | 2001 |
Adhesion to fibronectin selectively protects Bcr-Abl+cells from DNA damage–induced apoptosis
H van der Kuip, AW Goetz, C Miething, J Duyster, WE Aulitzky |
Blood | 2001 |
Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr-Abl transformed cells
I Gaston, PE Stenberg, A Bhat, BJ Druker |
Experimental Hematology | 2000 |
c-Abl expression in oral squamous cell carcinomas
T Yanagawa, H Harada, S Iwasa, K Tabuchi, K Omura, H Suzuki, H Yusa, K Yamagata, K Onizawa, T Ishii, H Yoshida |
Oral Oncology | 2000 |
Light Microscopic Detection of BCR-ABL Transcripts after In-Cell RT-PCR: Fusion Gene Expression Might Correlate with Clinical Evolution of Chronic Myeloid Leukemia
G Balatzenko, M Guenova |
Leukemia & Lymphoma | 2000 |
Cytoplasmic and nuclear localization of the 130 and 160 kDa Bcr proteins
E Laurent, M Talpaz, M Wetzler, R Kurzrock |
Leukemia | 2000 |
Molecular Abnormalities in Chronic Myeloid Leukemia: Deregulation of Cell Growth and Apoptosis
AD Bacco, K Keeshan, SL McKenna, TG Cotter |
The oncologist | 2000 |
Cycling, stressed-out and nervous: cellular functions of c-Abl
RA van Etten |
Trends in Cell Biology | 1999 |
Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics
Branford, Hughes, Rudzki |
British Journal of Haematology | 1999 |
ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5
D Smedley, A Demiroglu, M Abdul-Rauf, C Heath, C Cooper, J Shipley, NC Cross |
Neoplasia (New York, N.Y.) | 1999 |
The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein
N Takeda, M Shibuya, Y Maru |
Proceedings of the National Academy of Sciences | 1999 |
BCR Binds to the Xeroderma Pigmentosum Group B Protein
Y Maru, T Kobayashi, K Tanaka, M Shibuya |
Biochemical and Biophysical Research Communications | 1999 |
Polarized distribution of Bcr-Abl in migrating myeloid cells and co-localization of Bcr-Abl and its target proteins
PA Skourides, SA Perera, R Ren |
Oncogene | 1999 |
BCR/ABL mRNA and the P210BCR/ABL Protein Are Downmodulated by Interferon- in Chronic Myeloid Leukemia Patients
F Pane, I Mostarda, C Selleri, R Salzano, AM Raiola, L Luciano, G Saglio, B Rotoli, F Salvatore |
Blood | 1999 |
Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors
T Jonuleit, C Peschel, R Schwab, H der Kuip, E Buchdunger, T Fischer, C Huber, WE Aulitzky |
British Journal of Haematology | 1998 |
Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia
C Eaves, J Cashman, A Eaves |
Leukemia Research | 1998 |
BIOLOGY OF CHRONIC MYELOGENOUS LEUKEMIA
CM Verfaillie |
Hematology/Oncology Clinics of North America | 1998 |
The Effect of Interferon-α on Beta-1 Integrin Mediated Adhesion and Growth Regulation in Chronic Myelogenous Leukemia
R Bhatia, CM Verfaillie |
Leukemia & Lymphoma | 1998 |
Expression and Function of the Megakaryocyte Growth and Development Factor Receptor in Acute Myeloid Leukemia Blasts
M Wetzler, SH Bernstein, H Baumann, KM Fries, C Stewart, L Blumenson, MR Baera, GP Herziga, CD Bloomfielda, JL Slack |
Leukemia & Lymphoma | 1998 |
Acute Leukemias VII
W Hiddemann, T Büchner, B Wörmann, J Ritter, U Creutzig, M Keating, W Plunkett |
1998 | |
The C-Terminus of c-Abl Is Required for Proliferation and Viability Signaling in a c-Abl/Erythropoietin Receptor Fusion Protein
K Okuda, A DAndrea, RA Etten, JD Griffin |
Blood | 1998 |
Suppression of Cell Proliferation and the Expression of abcr-abl Fusion Gene and Apoptotic Cell Death in a New Human Chronic Myelogenous Leukemia Cell Line, KT-1, by Interferon-α
K Yanagisawa, H Yamauchi, M Kaneko, H Kohno, H Hasegawa, S Fujita |
Blood | 1998 |
Phosphorylation of Enabled by the Drosophila Abelson Tyrosine Kinase Regulates the In Vivo Function and Protein-Protein Interactions of Enabled
AR Comer, SM Ahern-Djamali, JL Juang, PD Jackson, FM Hoffmann |
Molecular and cellular biology | 1998 |
BCR/ABL induces multiple abnormalities of cytoskeletal function
R Salgia, JL Li, DS Ewaniuk, W Pear, E Pisick, SA Burky, T Ernst, M Sattler, LB Chen, JD Griffin |
Journal of Clinical Investigation | 1997 |
Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL
M Sattler, R Salgia |
Cytokine & Growth Factor Reviews | 1997 |
Abl expression in human fetal and adult tissues, tumours and tumour microvessels
AJ O'Neill, TG Cotter, JM Russell, EF Gaffney |
The Journal of Pathology | 1997 |
Signal transduction by wild-type and leukemogenic Abl proteins
AB Raitano, YE Whang, CL Sawyers |
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer | 1997 |
The amphiphysin-like protein 1 (ALP1) interacts functionally with the cABL tyrosine kinase and may play a role in cytoskeletal regulation
L Kadlec, AM Pendergast |
Proceedings of the National Academy of Sciences | 1997 |
The murine AIDS virus Gag precursor protein binds to the SH3 domain of c-Abl
P Dupraz, N Rebai, SJ Klein, N Beaulieu, P Jolicoeur |
Journal of virology | 1997 |
STEM CELLS IN CHRONIC MYELOGENOUS LEUKEMIA
CM Verfaillie |
Hematology/Oncology Clinics of North America | 1997 |
Apoptosis in Chronic Myelogenous Leukemia: Studies of Stage-Specific Differences
H Gisslinger, R Kurzrock, M Wetzler, S Tucker, H Kantarjian, B Robertson, M Talpaz |
Leukemia & Lymphoma | 1997 |
The Src Family Kinase Hck Interacts with Bcr-Abl by a Kinase-independent Mechanism and Phosphorylates the Grb2-binding Site of Bcr
M Warmuth, M Bergmann, A Prieß, K Häuslmann, B Emmerich, M Hallek |
The Journal of biological chemistry | 1997 |
Acute Leukemias VI
T Büchner, G Schellong, J Ritter, U Creutzig, W Hiddemann, B Wörmann |
1997 | |
Naturally Processed Tissue- and Differentiation Stage-Specific Autologous Peptides Bound by HLA Class I and II Molecules of Chronic Myeloid Leukemia Blasts
KP Papadopoulos, N Suciu-Foca, CS Hesdorffer, S Tugulea, A Maffei, PE Harris |
Blood | 1997 |
Chronic myelogenous leukemia: an update on the biological findings and therapeutic approaches
A Ferrajoli, M Fizzotti, AM Liberati, F Grignani |
Critical Reviews in Oncology/Hematology | 1996 |
The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products
ST Wen, PK Jackson, RA van Etten |
The EMBO Journal | 1996 |
BCR/ABL and leukemia
A Butturini, RB Arlinghaus, RP Gale |
Leukemia Research | 1996 |
Treatment of marrow stroma with interferon-alpha restores normal beta 1 integrin-dependent adhesion of chronic myelogenous leukemia hematopoietic progenitors. Role of MIP-1 alpha
R Bhatia, PB McGlave, CM Verfaillie |
Journal of Clinical Investigation | 1995 |
Increased neutrophil respiratory burst in bcr-null mutants
JW Voncken, H Schaick, V Kaartinen, K Deemer, T Coates, B Landing, P Pattengale, O Dorseuil, GM Bokoch, J Groffen, N Heisterkamp |
Cell | 1995 |
Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin
M Wetzler, M Talpaz, G Yee, SA Stass, RA van Etten, M Andreeff, AM Goodacre, HD Kleine, RK Mahadevia, R Kurzrock |
Proceedings of the National Academy of Sciences | 1995 |
Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function
R Bhatia, EA Wayner, PB McGlave, CM Verfaillie |
Journal of Clinical Investigation | 1994 |
Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies
M Talpaz, Z Estrov, H Kantarjian, S Ku, A Foteh, R Kurzrock |
Journal of Clinical Investigation | 1994 |
Cell Death in the Myeloid Lineage
TG Cotter, RS Fernandes, S Verhaegln, JV McCarthy |
Immunological Reviews | 1994 |
The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity
RA van Etten, PK Jackson, D Baltimore, MC Sanders, PT Matsudaira, PA Janmey |
The Journal of Cell Biology | 1994 |
Acute Leukemias
T Büchner, G Schellong, W Hiddemann, D Urbanitz, J Ritter |
1987 |